Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis

In VitroAntifungal Susceptibility of Clinically Relevant Species Belonging to Aspergillus SectionFlavi

(2013) Sarah S. Gonçalves et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole

(2012) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies

(2012) Camilla Colozza et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Comparison of Three Statistical Methods for Establishing Tentative Wild-Type Population and Epidemiological Cutoff Values for Echinocandins, Amphotericin B, Flucytosine, and Six Candida Species as Determined by the Colorimetric Sensititre YeastOne Method

(2012) E. Canton et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In vitroantifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole

(2012) Shivaprakash M. Rudramurthy et al.   MYCOSES

Aspergillus flavus

(2011) Saori Amaike et al.   Annual Review of Phytopathology

Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a NewIn VitroPharmacokinetic/Pharmacodynamic Model

(2011) Joseph Meletiadis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

(2011) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Technical note on Amphotericin B

(2011) C. Lass-Flörl et al.   CLINICAL MICROBIOLOGY AND INFECTION

Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation

(2011) Nuran Salman et al.   Expert Review of Anti-Infective Therapy

In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs

(2011) M. R. Shivaprakash et al.   MYCOSES

Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus

(2009) E. Spreghini et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Atypical Aspergillus flavus Isolates Associated with Chronic Azole Therapy

(2009) M. E. Brandt et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

(2009) J. W. Baddley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Aspergillus flavus: an emerging non-fumigatus Aspergillusspecies of significance

(2009) Suganthini Krishnan et al.   MYCOSES

Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

(2008) C. Lass-Florl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differences in pathogenicity and clinical syndromes due toAspergillus fumigatusandAspergillus flavus

(2008) Alessandro C. Pasqualotto   MEDICAL MYCOLOGY